SpliceBio has raised $135M in Series B funding, led by EQT Life Sciences and Sanofi Ventures, to advance its lead gene therapy candidate for Stargardt disease.
PRIVATEJun 11, 2025
Amount Raised
$135 Million
Round Type
Series B
BarcelonaBiotechnologySoftwareScience And Engineering
SpliceBio, a Barcelona-based clinical-stage genetic medicines company, raised $135M in Series B funding. The round was led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors. The funds will support the clinical development of its gene therapy candidate SB-007 for Stargardt disease. Key investors will join the SpliceBio Board of Directors.
Who to call at SpliceBio, and when
A new round usually means SpliceBio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day SpliceBio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at SpliceBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SpliceBio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
SpliceBio
Location
Barcelona, Catalonia, Spain
About
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SpliceBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BarcelonaBiotechnologySoftwareScience And Engineering